Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2019

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Glibenclamide (Amglidia®) has been rejected for use in the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.

Triptorelin acetate (Decapeptyl®) has been accepted for us as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy. For this indication, treatment initiation would normally be recommended by a specialist. This decision takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of triptorelin. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2019' on Email Share 'SMC Update - October 2019' on Delicious Share 'SMC Update - October 2019' on Digg Share 'SMC Update - October 2019' on Facebook Share 'SMC Update - October 2019' on reddit Share 'SMC Update - October 2019' on Twitter

CKS Updates - September 2019

During September 2019 Clinical Knowledge Summaries were published or updated in the following areas.

The End of life care in children is new. The Hypercalcaemia topic has been significantly restructured in line with current evidence with new sections added covering prognosis and specialist assessment. The Leg ulcer - venous topic contains updated recommendations on managing an infected leg ulcer. The Retinal detachment topic has also been updated in line with current evidence and contains new sections on assessment and specialist management. The other topics have undergone reviews and minor restructures.

Action: Clinicians who see patients with any of these conditions may find the new and updated information useful when reviewing current clinical practice.

Share 'CKS Updates - September 2019' on Email Share 'CKS Updates - September 2019' on Delicious Share 'CKS Updates - September 2019' on Digg Share 'CKS Updates - September 2019' on Facebook Share 'CKS Updates - September 2019' on reddit Share 'CKS Updates - September 2019' on Twitter

NICE Guidance - September 2019

The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2019. This month there are three guidelines that impact upon primary care.

The Attention deficit hyperactivity disorder guideline has been updated. It covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children, young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD. The updated advises that an ECG is not necessary before starting stimulants, atomoxetine or guanfacine if cardiovascular history and examination are normal and the person is not on medicine that poses an increased cardiovascular risk.

The Pneumonia in adults guideline has been updated. It covers diagnosing and managing community- and hospital-acquired pneumonia in adults. The update withdrew some recommendations that have been replaced by antimicrobial prescribing guidance.

The Pneumonia (community-acquired): antimicrobial prescribing guideline has been published. It sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with a confirmed diagnosis of community-acquired pneumonia. It aims to optimise antibiotic use and reduce antibiotic resistance.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'NICE Guidance - September 2019' on Email Share 'NICE Guidance - September 2019' on Delicious Share 'NICE Guidance - September 2019' on Digg Share 'NICE Guidance - September 2019' on Facebook Share 'NICE Guidance - September 2019' on reddit Share 'NICE Guidance - September 2019' on Twitter

Drug Safety Update - September 2019

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for September 2019 (PDF).

This month clinicians are advised that fingolimod (Gilenya®) has been associated with an increased risk of congenital malformations. It is recommended that women of childbearing potential must use effective contraception during fingolimod treatment and for 2 months after discontinuation.

Also this month pentosan polysulfate (Elmiron®) has been rarely linked with pigmentary maculopathy leading to visual impairment. Patients taking this drug are advised to have regular ophthalmic examinations and to promptly seek medical advice in case of visual changes.

Clinicians are also reminded of the risk of neuropsychiatric reactions associated with montelukast (Singulair®). Clinicians are reminded to be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the benefits and risks of continuing treatment if they occur.

The summary of letters to healthcare professionals this month includes a notification letter from Santen warning of the risk of medication error during a transition to a new bottle design. Affected products include Cosopt®, Trusopt® and Timoptol®.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.

Share 'Drug Safety Update - September 2019' on Email Share 'Drug Safety Update - September 2019' on Delicious Share 'Drug Safety Update - September 2019' on Digg Share 'Drug Safety Update - September 2019' on Facebook Share 'Drug Safety Update - September 2019' on reddit Share 'Drug Safety Update - September 2019' on Twitter

SMC Update - September 2019

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Melatonin prolonged-release (Slenyto®) has been rejected for use in the treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. The justification of the treatment's cost in relation to its health benefits was not sufficient and in addition the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by SMC.

Dapagliflozin (Forxiga®) has been accepted for use in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥27kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Ospemifene (Senshio®) has been accepted for use in the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - September 2019' on Email Share 'SMC Update - September 2019' on Delicious Share 'SMC Update - September 2019' on Digg Share 'SMC Update - September 2019' on Facebook Share 'SMC Update - September 2019' on reddit Share 'SMC Update - September 2019' on Twitter

« Older Posts

Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer